With over 4.89 million Iovance Biotherapeutics Inc (IOVA) shares trading Friday and a closing price of $5.79 on the day, the dollar volume was approximately $28.33 million. The shares have shown a negative half year performance of -24.71% and its price on 11/24/23 gained nearly 7.32%. Currently, there are 255.92M common shares owned by the public and among those 197.87M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 14 analysts who have offered their price forecasts for IOVA have a consensus price objective of $20.42. The analysts have set the share’s price value over the next 12 months at a high of $30.00 and a low of $12.00. The average price target is 71.65% above its recent price level and an upside to the estimated low will see the stock gain 51.75% over that period. But an upside of 80.7% will see the stock hit the forecast high price target while median target price for the stock is $19.00.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Shares of Iovance Biotherapeutics Inc (NASDAQ: IOVA) opened at $5.48, up $0.09 from a prior closing price of $5.39. However, the script later moved the day high at 5.95, up 7.32%. The company’s stock has a 5-day price change of 31.59% and -5.85% over the past three months. IOVA shares are trading -9.39% year to date (YTD), with the 12-month market performance down to -7.80% lower. It has a 12-month low price of $3.21 and touched a high of $9.36 over the same period. IOVA has an average intraday trading volume of 6.82 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 34.02%, 35.30%, and -8.21% respectively.
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 73.20% of the company’s 255.92M shares outstanding.
It has a market capitalization of $1.48B and a beta (3y monthly) value of 0.28. The earnings-per-share (ttm) stands at -$2.08. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.02% over the week and 8.56% over the month.
Analysts forecast that Iovance Biotherapeutics Inc (IOVA) will achieve an EPS of -$0.44 for the current quarter, -$0.36 for the next quarter and -$1.37 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.53 while analysts give the company a high EPS estimate of -$0.34. Comparatively, EPS for the current quarter was -$0.64 a year ago. Earnings per share for the fiscal year are expected to increase by 24.78%, and 26.57% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 14 brokerage firm advisors rate Iovance Biotherapeutics Inc (IOVA) as a “Strong Buy” at a consensus score of 1.29. Specifically, 11 Wall Street analysts polled rate the stock as a buy, while 1 of the 14 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IOVA, a number of firms have released research notes about the stock. Goldman stated their Buy rating for the stock in a research note on November 20, 2023, with the firm’s price target at $12.